Zosano Pharma Corporation (ZSAN) Earns Media Sentiment Rating of 0.18
News articles about Zosano Pharma Corporation (NASDAQ:ZSAN) have been trending somewhat positive recently, according to Accern. The research firm scores the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zosano Pharma Corporation earned a news sentiment score of 0.18 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.9008537130321 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the headlines that may have impacted Accern Sentiment’s rankings:
- Zosano Pharma Corp (ZSAN) Shares Moving On Volume – FLBC News (flbcnews.com)
- Calling all Bargain Hunters: Stock Update on Zosano Pharma Corporation (NASDAQ:ZSAN) – FLBC News (flbcnews.com)
- What Are The Technicals Telling Us About Zosano Pharma Corp (ZSAN) – Evergreen Caller (evergreencaller.com)
- Zosano Pharma Corp (ZSAN) A Look Inside the Technicals – Evergreen Caller (evergreencaller.com)
Separately, ValuEngine upgraded shares of Zosano Pharma Corporation from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 6th.
Shares of Zosano Pharma Corporation (ZSAN) traded up 10.4524% during trading on Friday, reaching $0.9278. 1,025,679 shares of the company’s stock traded hands. The company has a 50 day moving average price of $1.06 and a 200 day moving average price of $1.54. Zosano Pharma Corporation has a 1-year low of $0.45 and a 1-year high of $3.54. The stock’s market capitalization is $36.40 million.
Zosano Pharma Corporation (NASDAQ:ZSAN) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. During the same quarter last year, the business posted ($0.54) earnings per share. On average, equities analysts forecast that Zosano Pharma Corporation will post ($0.79) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Zosano Pharma Corporation (ZSAN) Earns Media Sentiment Rating of 0.18” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/01/zosano-pharma-corporation-zsan-earns-media-sentiment-rating-of-0-18.html.
About Zosano Pharma Corporation
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Stock Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related stocks with our FREE daily email newsletter.